MIDI explores the current landscape of CAR T-cell therapy manufacturing and its impact on patient treatment. MIDI's CEO, Christopher Montalbano, sheds light on the challenges posed by the centralized manufacturing approach and delves into the promising alternative: Point-of-Care manufacturing.

Chris breaks down the centralized manufacturing workflow for autologous CAR T-cell therapy, emphasizing the collection of T-cells from patients, their transportation to a centralized lab for genetic manipulation and cell expansion, and the subsequent infusion back into the patient. While highlighting the benefits of this therapy, he unveils the critical issues arising from the current centralized approach, such as limited access, manufacturing constraints, high costs, labor-intensive processes, and the need for specialized facilities.

Tune into this episode and explore the paradigm shift toward Point-of-Care manufacturing, an approach that can revolutionize CAR T-cell therapy by bringing manufacturing and treatment to the patient's care site enabling commercial-scale production and economies of scale reducing costs, shortening manufacturing timelines, minimizing contamination risks, and preserving cell quality.

Tune in to this episode and join the journey toward democratizing CAR T-cell therapy.